FY2019 Earnings Estimate for Genmab A/S Issued By Jefferies Financial Group (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB) – Stock analysts at Jefferies Financial Group raised their FY2019 EPS estimates for shares of Genmab A/S in a note issued to investors on Wednesday, November 6th. Jefferies Financial Group analyst P. Welford now expects that the company will post earnings of $0.60 per share for the year, up from their previous estimate of $0.56. Jefferies Financial Group also issued estimates for Genmab A/S’s Q4 2019 earnings at $0.42 EPS, FY2020 earnings at $0.36 EPS, FY2021 earnings at $0.61 EPS, FY2022 earnings at $0.87 EPS and FY2023 earnings at $1.10 EPS.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, August 14th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.13. The firm had revenue of $116.49 million for the quarter.

GMAB has been the subject of a number of other reports. JPMorgan Chase & Co. raised Genmab A/S from a “neutral” rating to an “overweight” rating and set a $23.00 price target for the company in a research note on Thursday, September 12th. Bank of America raised Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Friday, September 13th. Guggenheim initiated coverage on Genmab A/S in a research note on Monday, August 12th. They set a “buy” rating for the company. Morgan Stanley initiated coverage on Genmab A/S in a research note on Monday, August 12th. They set an “overweight” rating for the company. Finally, Royal Bank of Canada initiated coverage on Genmab A/S in a research note on Monday, August 12th. They set an “outperform” rating and a $23.00 price target for the company. Six investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $23.67.

Shares of Genmab A/S stock opened at $22.12 on Monday. The company’s 50 day moving average price is $20.70. Genmab A/S has a 12 month low of $13.64 and a 12 month high of $22.20. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.89 and a quick ratio of 14.89.

Large investors have recently bought and sold shares of the company. Private Capital Group LLC bought a new stake in shares of Genmab A/S in the 2nd quarter valued at approximately $41,000. Signaturefd LLC bought a new stake in shares of Genmab A/S in the 3rd quarter valued at approximately $48,000. LVW Advisors LLC bought a new stake in shares of Genmab A/S in the 3rd quarter valued at approximately $201,000. Moloney Securities Asset Management LLC bought a new stake in shares of Genmab A/S in the 3rd quarter valued at approximately $238,000. Finally, Cerity Partners LLC bought a new stake in shares of Genmab A/S in the 3rd quarter valued at approximately $250,000. 0.99% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Further Reading: What does EPS mean?

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.